Italy Fines Apple €98.6 Million Over App Store Dominance 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
ROCKVILLE, Md., Aug. 01, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, August 8, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 53241624. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 617-340-6072 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
